Needham & Company Boosts Price Target on Par Pharmaceutical Companies Incorporated (PRX)

By admin | 6 years ago

Investment analysts at Needham & Company upped their target price on shares of Par Pharmaceutical Companies Incorporated (NYSE: PRX) from $42.00 to $48.00 in a note issued to investors on Wednesday. The firm currently has a “strong-buy” rating on the stock.

Par Pharmaceutical Companies Incorporated opened at 41.25 on Wednesday. Par Pharmaceutical Companies Incorporated has a 1-year low of $24.85 and a 1-year high of $42.25. The company’s market cap is $1.493 billion.

Par Pharmaceutical Companies Incorporated last released its earnings data on Tuesday, May 8th. The company reported $0.80 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.72 by $0.08. The company’s quarterly revenue was up 16.5% on a year-over-year basis. Analysts expect that Par Pharmaceutical Companies Incorporated will post $1.10 EPS next quarter.

Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of Par Pharmaceutical Companies Incorporated in a research note to investors on Thursday, April 19th. They set an “overweight” rating on the stock. Analysts at JPMorgan Chase (NYSE: JPM) initiated coverage on shares of Par Pharmaceutical Companies Incorporated in a research note to investors on Friday, March 16th. They set a “neutral” rating and a $40.00 price target on the stock.

Par Pharmaceutical Companies, Inc., is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc.

About the author